vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $359.3M, roughly 2.0× PROCORE TECHNOLOGIES, INC.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -2.5%, a 21.6% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 15.7%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 12.4%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
MEDP vs PCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $359.3M |
| Net Profit | $135.1M | $-9.1M |
| Gross Margin | — | 80.1% |
| Operating Margin | 21.6% | 15.5% |
| Net Margin | 19.1% | -2.5% |
| Revenue YoY | 32.0% | 15.7% |
| Net Profit YoY | 15.5% | 72.4% |
| EPS (diluted) | $4.65 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $359.3M | ||
| Q4 25 | $708.5M | $349.1M | ||
| Q3 25 | $659.9M | $338.9M | ||
| Q2 25 | $603.3M | $323.9M | ||
| Q1 25 | $558.6M | $310.6M | ||
| Q4 24 | $536.6M | $302.0M | ||
| Q3 24 | $533.3M | $295.9M | ||
| Q2 24 | $528.1M | $284.3M |
| Q1 26 | — | $-9.1M | ||
| Q4 25 | $135.1M | $-37.6M | ||
| Q3 25 | $111.1M | $-9.1M | ||
| Q2 25 | $90.3M | $-21.1M | ||
| Q1 25 | $114.6M | $-33.0M | ||
| Q4 24 | $117.0M | $-62.3M | ||
| Q3 24 | $96.4M | $-26.4M | ||
| Q2 24 | $88.4M | $-6.3M |
| Q1 26 | — | 80.1% | ||
| Q4 25 | — | 80.1% | ||
| Q3 25 | — | 79.7% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 79.1% | ||
| Q4 24 | — | 81.2% | ||
| Q3 24 | — | 81.4% | ||
| Q2 24 | — | 83.1% |
| Q1 26 | — | 15.5% | ||
| Q4 25 | 21.6% | -12.3% | ||
| Q3 25 | 21.5% | -4.4% | ||
| Q2 25 | 20.9% | -9.3% | ||
| Q1 25 | 20.3% | -11.7% | ||
| Q4 24 | 23.4% | -21.9% | ||
| Q3 24 | 21.1% | -12.3% | ||
| Q2 24 | 19.9% | -5.2% |
| Q1 26 | — | -2.5% | ||
| Q4 25 | 19.1% | -10.8% | ||
| Q3 25 | 16.8% | -2.7% | ||
| Q2 25 | 15.0% | -6.5% | ||
| Q1 25 | 20.5% | -10.6% | ||
| Q4 24 | 21.8% | -20.6% | ||
| Q3 24 | 18.1% | -8.9% | ||
| Q2 24 | 16.7% | -2.2% |
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $4.65 | $-0.25 | ||
| Q3 25 | $3.86 | $-0.06 | ||
| Q2 25 | $3.10 | $-0.14 | ||
| Q1 25 | $3.67 | $-0.22 | ||
| Q4 24 | $3.67 | $-0.42 | ||
| Q3 24 | $3.01 | $-0.18 | ||
| Q2 24 | $2.75 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $386.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $1.2B |
| Total Assets | $2.0B | $2.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $386.0M | ||
| Q4 25 | $497.0M | $768.5M | ||
| Q3 25 | $285.4M | $684.0M | ||
| Q2 25 | $46.3M | $620.9M | ||
| Q1 25 | $441.4M | $566.7M | ||
| Q4 24 | $669.4M | $775.4M | ||
| Q3 24 | $656.9M | $756.9M | ||
| Q2 24 | $510.9M | $735.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $459.1M | $1.3B | ||
| Q3 25 | $293.6M | $1.2B | ||
| Q2 25 | $172.4M | $1.2B | ||
| Q1 25 | $593.6M | $1.2B | ||
| Q4 24 | $825.5M | $1.3B | ||
| Q3 24 | $881.4M | $1.3B | ||
| Q2 24 | $763.6M | $1.3B |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.0B | $2.2B | ||
| Q3 25 | $1.8B | $2.1B | ||
| Q2 25 | $1.6B | $2.0B | ||
| Q1 25 | $1.9B | $1.9B | ||
| Q4 24 | $2.1B | $2.1B | ||
| Q3 24 | $2.1B | $2.0B | ||
| Q2 24 | $1.9B | $2.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $76.8M |
| Free Cash FlowOCF − Capex | $188.1M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $76.8M | ||
| Q4 25 | $192.7M | $114.9M | ||
| Q3 25 | $246.2M | $88.5M | ||
| Q2 25 | $148.5M | $30.8M | ||
| Q1 25 | $125.8M | $66.0M | ||
| Q4 24 | $190.7M | $29.1M | ||
| Q3 24 | $149.1M | $39.3M | ||
| Q2 24 | $116.4M | $58.7M |
| Q1 26 | — | — | ||
| Q4 25 | $188.1M | $109.2M | ||
| Q3 25 | $235.5M | $83.1M | ||
| Q2 25 | $142.4M | $27.9M | ||
| Q1 25 | $115.8M | $62.0M | ||
| Q4 24 | $183.0M | $17.4M | ||
| Q3 24 | $138.5M | $35.7M | ||
| Q2 24 | $103.5M | $56.8M |
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 31.3% | ||
| Q3 25 | 35.7% | 24.5% | ||
| Q2 25 | 23.6% | 8.6% | ||
| Q1 25 | 20.7% | 20.0% | ||
| Q4 24 | 34.1% | 5.8% | ||
| Q3 24 | 26.0% | 12.1% | ||
| Q2 24 | 19.6% | 20.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 1.6% | ||
| Q3 25 | 1.6% | 1.6% | ||
| Q2 25 | 1.0% | 0.9% | ||
| Q1 25 | 1.8% | 1.3% | ||
| Q4 24 | 1.4% | 3.9% | ||
| Q3 24 | 2.0% | 1.2% | ||
| Q2 24 | 2.4% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
PCOR
Segment breakdown not available.
